Low-dose rapamycin increased cerebral blood flow in healthy, middle-aged carriers of the APOE4 gene — the strongest genetic risk factor for late-onset Alzheimer's disease — with the largest gains seen in women.
The Research
Led by Ai-Ling Lin, Ph.D., a professor at the University of Missouri School of Medicine and an investigator at the Roy Blunt NextGen Precision Health building, the pilot clinical trial enrolled cognitively healthy adults aged 45 to 65. All participants were genetically screened for APOE4 status; none showed memory impairment or dementia symptoms.
Participants took a daily low dose of rapamycin — an FDA-approved immunosuppressant used to prevent organ transplant rejection and treat rare lung conditions — for four weeks. Neuroimaging then measured cerebral blood flow.
The results, published in the Journal of Cerebral Blood Flow & Metabolism, were genotype-dependent. Only APOE4 carriers showed significant increases in cerebral perfusion. Non-carriers on the same regimen showed no comparable vascular change.
Female APOE4 carriers saw the greatest improvements. This matters because women make up nearly two-thirds of people diagnosed with Alzheimer's, and female APOE4 carriers tend to decline faster than men with the same genotype.
"Alzheimer's tends to happen more in older people, especially for those with APOE4," Lin said. "If we can slow down aging in the brain for those people most at risk, maybe we can reduce the risk of them developing Alzheimer's disease."
Prior to this human trial, Lin's lab showed that rapamycin restored cerebral blood flow and slowed neurological aging in transgenic APOE4 mice. The new study suggests those effects may translate to people decades before clinical symptoms appear.
Why It Matters
Years before amyloid plaques or tau tangles accumulate, many APOE4 carriers show chronic hypoperfusion — reduced blood flow to memory hubs like the hippocampus. Healthy neurons depend on steady microvascular perfusion for oxygen and metabolic waste clearance. When that delivery falters, neural aging accelerates.
This trial is small and preliminary, and rapamycin is not approved for Alzheimer's prevention. But it supports a broader idea: vascular deficits tied to genetic risk may be modifiable long before cognitive decline. That window — ages 45 to 65, while the brain is still healthy — is where precision prevention may eventually matter most.
What You Can Do
- Know your APOE status if you have a family history of Alzheimer's; ask a doctor or genetic counselor.
- Protect vascular health now: manage blood pressure, stay active, sleep well, and limit alcohol.
- Avoid unapproved rapamycin for prevention — dosing and long-term safety in healthy adults are still being studied.
- Track your own cognition over time with objective tests so changes are easier to spot early.
Source: Neuroscience News
Curious about your own brain? Take our free adaptive IQ test or try 306 brain training levels.